Today: 9 June 2026
BigBear.ai stock slides as dilution vote nears; CEO filing adds to the focus
4 February 2026
2 mins read

BigBear.ai stock slides as dilution vote nears; CEO filing adds to the focus

New York, Feb 4, 2026, 10:54 EST — Regular session

  • BigBear.ai shares dropped in morning trading ahead of a vote on increasing the company’s authorised share count
  • A recent SEC filing revealed shares were withheld from CEO Kevin McAleenan to cover taxes on his vested stock awards
  • Shares of AI-related software companies swung unevenly as concerns grew over the rapid pace at which new AI tools might upend parts of the industry

BigBear.ai Holdings, Inc (NYSE: BBAI) saw its shares drop 6.1% to $4.65 during Wednesday morning trading. The stock had climbed to $5.00 before sliding to a low of $4.58, as roughly 14.6 million shares exchanged hands.

The timing is key as investors approach a shareholder vote to raise the cap on BigBear.ai’s authorized common shares. While this change won’t trigger an immediate stock sale, it paves the way for potential fundraising or stock-based transactions down the line, which could dilute current shareholders.

BigBear.ai is aiming to expand past its usual U.S. government contracts, targeting ports, border operations, and trade-focused applications. Still, the conversation around the stock keeps circling back to a single issue: how much leeway management seeks, and what they plan to do with that freedom.

In a proxy filing, the company announced its adjourned special meeting will resume on Feb. 18 at 2:00 p.m. Eastern. Shareholders will vote on a proposal to raise authorized common shares from 500 million to 1 billion. The board supports the move, citing plans to use the added equity for financing, retention awards, and potential strategic partnerships.

A Form 4 filed Wednesday revealed that CEO Kevin McAleenan sold 48,691 shares at $6.26 each on Jan. 15. The filing noted these shares were withheld to cover tax liabilities from vested restricted stock units. After the sale, McAleenan still held 1,165,294 shares directly.

On Tuesday, Pomerantz LLP announced it is probing allegations on behalf of BigBear.ai investors, focusing on possible securities fraud or other illegal business activities. The firm flagged the notice as attorney advertising.

Software and data stocks felt the heat amid a broader selloff fueled by concerns that emerging AI tools might disrupt the sector. Nvidia CEO Jensen Huang dismissed those fears as “illogical,” Reuters reported. Reuters

AI-related stocks showed a mixed bag: Palantir Technologies dropped roughly 10%, and SoundHound AI slipped around 4%. Meanwhile, C3.ai climbed about 2%.

BigBear.ai is pushing a trade-and-border angle. On Jan. 28, it announced a strategic partnership with AD Ports Group’s Maqta Technologies to explore AI-driven customs management systems for ports and borders. McAleenan called the collaboration with AD Ports Group “delightful.” BigBear.ai Holdings, Inc.

In early January, the company announced it had bought specific technologies from CargoSeer, a firm specializing in cargo inspection and trade-risk software, for an undisclosed sum. “We are expanding our ability to support customs agencies as they modernize enforcement operations,” McAleenan said in the announcement. BigBear.ai

The key risk lies in the vote itself. Should the share-authorisation proposal pass, investors might continue to price in dilution concerns. If it’s rejected, BigBear.ai loses flexibility to raise capital through equity or strike deals. Cantor Fitzgerald’s Jonathan Ruykhaver downgraded the stock to “neutral” in early January, pointing to go-to-market hurdles and tightening margins, according to Investing.com.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Apple stock jumps as Goldman flags App Store spending pickup, keeping AAPL in focus
Previous Story

Apple stock jumps as Goldman flags App Store spending pickup, keeping AAPL in focus

Coinbase stock slides after Nevada lawsuit over sports event contracts; earnings ahead
Next Story

Coinbase stock slides after Nevada lawsuit over sports event contracts; earnings ahead

Go toTop